Increased plasma microRNA and CD133/CK18‑positive cancer cells in the pleural fluid of a pancreatic cancer patient with liver and pleural metastases and correlation with chemoresistance
- Authors:
- Chuanli Ren
- Hui Chen
- Chongxu Han
- Daxin Wang
- Deyuan Fu
View Affiliations
Affiliations: Medical Laboratory, Northern Jiangsu People's Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, P.R China, Geriatric Medicine Department, Northern Jiangsu People's Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, P.R China, Research Centre of Biomedical Engineering, Northern Jiangsu People's Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, P.R China, General Surgery Department, Northern Jiangsu People's Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, P.R China
- Published online on: July 13, 2012 https://doi.org/10.3892/ol.2012.798
-
Pages:
691-694
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
We report a case of notably increased plasma levels of microRNA (miR)‑21, miR‑25, miR‑103 and miR‑151 in a pancreatic cancer patient with liver and pleural metastases. CD45‑coated immunomagnetic beads detected an enrichment of malignant cancer cells in the pleural fluid, and CD133+CK18+ cancer cells were identified. Using computer tomography (CT) combined with cancer cells stained in the pleural fluid, a previously healthy 60‑year‑old male was diagnosed with pancreatic cancer with multiple liver tumor metastases. Cancer antigen 19‑9 (CA19‑9), alkaline phosphatase (ALP) and γ‑glutamate‑transpeptidase (γ‑GT) were notably increased in the serum, and carcinoembryonic antigen (CEA) was increased in the pleural fluid. The patient succumbed to the disease three months following standard chemotherapy. The increased levels of plasma miR‑21, miR‑25, miR‑103 and miR‑151, as well as the identification of CD133+CK18+ cells in the pleural fluid of a pancreatic cancer patient with liver metastases, may regulate the molecular mechanisms involved in chemoresistance. The patient was insensitive to chemotherapy and succumbed 3 months later. Full elucidation of the molecular and pathological features of pancreatic cancer may be a novel strategy for diagnosis and tailored therapy.
View References
|
1.
|
PC HermannSL HuberT HerrlerDistinct
populations of cancer stem cells determine tumor growth and
metastatic activity in human pancreatic cancerCell Stem
Cell1313323200710.1016/j.stem.2007.06.00218371365
|
|
2.
|
Z WangY LiA AhmadPancreatic cancer:
understanding and overcoming chemoresistanceNat Rev Gastroenterol
Hepatol82733201110.1038/nrgastro.2010.18821102532
|
|
3.
|
JB StokesSJ AdairJK Slack-DavisInhibition
of focal adhesion kinase by PF-562,271 inhibits the growth and
metastasis of pancreatic cancer concomitant with altering the tumor
micro-environmentMol Cancer
Ther1021352145201110.1158/1535-7163.MCT-11-026121903606
|
|
4.
|
C RenC HanJ ZhangDetection of apoptotic
circulating tumor cells in advanced pancreatic cancer following
5-fluorouracil chemotherapyCancer Biol
Ther12700706201110.4161/cbt.12.8.1596021811100
|
|
5.
|
J LiuJ GaoY DuCombination of plasma
microRNAs with serum CA19-9 for early detection of pancreatic
cancerInt J Cancer131683691201110.1002/ijc.2642221913185
|
|
6.
|
JY ParkJ HelmD CoppolaD KimM MalafaSJ
KimMicroRNAs in pancreatic ductal adenocarcinomaWorld J
Gastroenterol17817827201110.3748/wjg.v17.i7.81721412491
|
|
7.
|
C RoldoE MissiagliaJP HaganMicroRNA
expression abnormalities in pancreatic endocrine and acinar tumors
are associated with distinctive pathologic features and clinical
behaviorJ Clin
Oncol2446774684200610.1200/JCO.2005.05.519416966691
|
|
8.
|
C RenP HeJ ZhangZ ZhengY QianX
ZhaoMalignant characteristics of circulating tumor cells and
corresponding primary tumor in a patient with esophageal squamous
cell carcinoma before and after surgeryCancer Biol
Ther11633638201110.4161/cbt.11.7.1495021307656
|
|
9.
|
AD RhimET MirekNM AielloEMT and
dissemination precede pancreatic tumor
formationCell148349361201210.1016/j.cell.2011.11.02522265420
|
|
10.
|
V AscoliS TaccognaCC ScalzoF NardiUtility
of cytokeratin 20 in identifying the origin of metastatic
carcinomas in effusionsDiagn
Cytopathol12303308199510.1002/dc.28401204047656755
|
|
11.
|
J YaoY AnJS WieCyclopamine reverts
acquired chemoresistance and down-regulates cancer stem cell
markers in pancreatic cancer cell linesSwiss Med
Wkly141w13208201121630164
|
|
12.
|
E GiovannettiN FunelGJ PetersMicroRNA-21
in pancreatic cancer: correlation with clinical outcome and
pharmacologic aspects underlying its role in the modulation of
gemcitabine activityCancer
Res7045284538201010.1158/0008-5472.CAN-09-446720460539
|
|
13.
|
S AliA AhmadS BanerjeeGemcitabine
sensitivity can be induced in pancreatic cancer cells through
modulation of miR-200 and miR-21 expression by curcumin or its
analogue CDFCancer
Res7036063617201010.1158/0008-5472.CAN-09-459820388782
|
|
14.
|
T MoriyamaK OhuchidaK MizumotoMicroRNA-21
modulates biological functions of pancreatic cancer cells including
their proliferation, invasion, and chemoresistanceMol Cancer
Ther810671074200910.1158/1535-7163.MCT-08-0592
|
